Health Care·Life Sciences Tools & Services·$8.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.85 | N/A | -1.85% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.85 | N/A | -1.85% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Overall, management maintained a neutral stance on the company's performance. They highlighted ongoing market challenges but did not offer specific future guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in the current market environment.
Bio-Techne Corp's earnings report showed a slight miss on EPS, which contributed to a 3.63% decline in stock price. The lack of revenue data and guidance may have added to investor uncertainty. Overall, the market reaction suggests cautious sentiment among investors regarding the company's near-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MONOLITHIC PWR SYS I
Oct 27, 2014